Skip to content

Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis

Development of Camera Based Gait Deviation Index for Persons With Multiple Sclerosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06516458
Acronym
MS-GDI
Enrollment
40
Registered
2024-07-24
Start date
2024-07-31
Completion date
2026-07-31
Last updated
2024-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Multiple Sclerosis Relapse, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive

Brief summary

The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).

Detailed description

In rehabilitation in general, in order to track patients' progress and provide next steps, there is a need for easily obtainable, understandable, and objective measures of ability. Currently, there is no measure that clinicians can utilize to determine walking quality. While Gait Deviation Index has been validated and can reliably be used in adults who experienced a Spinal Cord Injury, it has not yet been validated in people with MS. After the MS-specific GDI is developed from this study, therapists and clinicians will be able use it as a reliable progress measure. Which may lead to the delivery of more effective therapy for patients with MS. Here we plan to measure body position with camera based tracking during your gait cycle.

Interventions

DIAGNOSTIC_TESTCamera Based Kinematic Analysis

Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis

Sponsors

Shirley Ryan AbilityLab
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of relapsing form of MS (including relapsing-remitting MS and secondary progressive MS) * Able to ambulate overground * Relapse free for at least 1 month * Age ≥18 and ≤ 75 years * Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening

Exclusion criteria

\- Orthopedic injuries, fractures, surgeries or other conditions affecting locomotor function or weight bearing

Design outcomes

Primary

MeasureTime frameDescription
Kinematics of the gait cycleat the time of sessionJoint position of lower limbs during a single cycle of gait

Secondary

MeasureTime frameDescription
6 minute walk testat the time of sessionyou will be instructed to walk as quickly and safely as you can while being timed for 6 minutes

Countries

United States

Contacts

Primary ContactWeena Dee
wdee@sralab.org312-328-7503
Backup ContactAlex Barry
abarry@sralab.org312-238-1435

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026